125 related articles for article (PubMed ID: 11166965)
1. Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration.
Boudinot E; Morin-Surun M; Foutz AS; Fournié-Zaluski M; Roques BP; Denavit-Saubié M
Pain; 2001 Feb; 90(1-2):7-13. PubMed ID: 11166965
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive effects of RB101(S), a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by (+)-HA966, a functional NMDA receptor antagonist: a c-Fos study in the rat spinal cord.
Buritova J; Le Guen S; Fournié-Zaluski MC; Roques BP; Besson JM
Eur J Pain; 2003; 7(3):241-9. PubMed ID: 12725847
[TBL] [Abstract][Full Text] [Related]
3. Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation.
Maldonado R; Valverde O; Turcaud S; Fournié-Zaluski MC; Roques BP
Pain; 1994 Jul; 58(1):77-83. PubMed ID: 7970841
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.
Noble F; Soleilhac JM; Soroca-Lucas E; Turcaud S; Fournie-Zaluski MC; Roques BP
J Pharmacol Exp Ther; 1992 Apr; 261(1):181-90. PubMed ID: 1560364
[TBL] [Abstract][Full Text] [Related]
5. Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine.
Noble F; Turcaud S; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 1992 Nov; 223(1):83-9. PubMed ID: 1478260
[TBL] [Abstract][Full Text] [Related]
6. RB101(S), a dual inhibitor of enkephalinases does not induce antinociceptive tolerance, or cross-tolerance with morphine: a c-Fos study at the spinal level.
Le Guen S; Noble F; Fournié-Zaluski MC; Roques BP; Besson JM; Buritova J
Eur J Pharmacol; 2002 Apr; 441(3):141-50. PubMed ID: 12063085
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of enkephalins catabolism inhibitor-induced antinociception by drugs classically used in pain management.
Nieto MM; Wilson J; Walker J; Benavides J; Fournié-Zaluski MC; Roques BP; Noble F
Neuropharmacology; 2001 Sep; 41(4):496-506. PubMed ID: 11543770
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
[TBL] [Abstract][Full Text] [Related]
9. Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice.
Noble F; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 1993 Jan; 230(2):139-49. PubMed ID: 8422896
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins.
Ruiz-Gayo M; Durieux C; Fournié-Zaluski MC; Roques BP
J Neurochem; 1992 Nov; 59(5):1805-11. PubMed ID: 1357099
[TBL] [Abstract][Full Text] [Related]
11. RB101-mediated protection of endogenous opioids: potential therapeutic utility?
Jutkiewicz EM
CNS Drug Rev; 2007; 13(2):192-205. PubMed ID: 17627672
[TBL] [Abstract][Full Text] [Related]
12. Further evidence for the interaction of mu- and delta-opioid receptors in the antinociceptive effects of the dual inhibitor of enkephalin catabolism, RB101(S). A spinal c-Fos protein study in the rat under carrageenin inflammation.
Le Guen S; Catheline G; Fournié-Zaluski MC; Roques BP; Besson JM; Buritova J
Brain Res; 2003 Mar; 967(1-2):106-12. PubMed ID: 12650971
[TBL] [Abstract][Full Text] [Related]
13. Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours.
Noble F; Benturquia N; Bilkei-Gorzo A; Zimmer A; Roques BP
Psychopharmacology (Berl); 2008 Feb; 196(2):327-35. PubMed ID: 17906961
[TBL] [Abstract][Full Text] [Related]
14. The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonist.
Le Guen S; Honoré P; Catheline G; Fournié-Zaluski MC; Roques BP; Besson JM
Brain Res; 1999 Jul; 834(1-2):200-6. PubMed ID: 10407116
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics of effects of mu-, delta-, and kappa-opioid agonists and enkephalinase inhibitor RB101 in rats of two inbred strains].
Sudakov SK; Liupina IuV; Medvedeva OF; Tiurina IV; Maldonado R
Biull Eksp Biol Med; 1998 May; 125(5):551-4. PubMed ID: 9644557
[No Abstract] [Full Text] [Related]
16. Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects.
Jutkiewicz EM; Torregrossa MM; Sobczyk-Kojiro K; Mosberg HI; Folk JE; Rice KC; Watson SJ; Woods JH
Eur J Pharmacol; 2006 Feb; 531(1-3):151-9. PubMed ID: 16442521
[TBL] [Abstract][Full Text] [Related]
17. Analgesic responses elicited by endogenous enkephalins (protected by mixed peptidase inhibitors) in a variety of morphine-sensitive noxious tests.
Schmidt C; Peyroux J; Noble F; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 1991 Jan; 192(2):253-62. PubMed ID: 2032557
[TBL] [Abstract][Full Text] [Related]
18. Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101.
Noble F; Coric P; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 1992 Nov; 223(1):91-6. PubMed ID: 1478261
[TBL] [Abstract][Full Text] [Related]
19. RB 101, a purported pro drug inhibitor of enkephalin metabolism, is antinociceptive in pregnant mice.
Jayaram A; Singh P; Noreuil T; Fournié-Zaluski MC; Carp HM
Anesth Analg; 1997 Feb; 84(2):355-8. PubMed ID: 9024028
[TBL] [Abstract][Full Text] [Related]
20. Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment.
Cordonnier L; Sanchez M; Roques BP; Noble F
Neuroscience; 2005; 135(1):1-10. PubMed ID: 16084652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
